Please login to the form below
Synagis
The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Synagis was produced by AstraZeneca and AbbVie.
Sobi shows strong growth despite haemophilia competition
November also saw Sobi acquire rights to Synagis, the only approved respiratory syncytial virus (RSV) prophylaxis for high-risk infants from AstraZeneca. ... We completed the acquisition of Synagis in late January and are in the process of integrating
US, EU regulators back rapid reviews of AZ’s RSV med
MEDI8897 is a longer-acting follow-up to AZ’s Synagis (palivizumab), which is currently the only drug approved for preventing RSV in high-risk patients. ... Synagis has been a nice earner for AZ, making almost $700m in revenues in 2017, but has started
FDA clears Sobi’s Gamifant for ‘hyper-inflammation’ disease
Earlier this month, Sobi agreed to acquire the US rights to AstraZeneca’s respiratory syncytial virus (RSV) prevention drug Synagis (palivizumab) in a deal worth $1.5bn. ... Sobi's Guido Oelkers. “Gamifant will add significant strength to Sobi’s
AZ cuts $1.5bn-plus deal to pass US drug rights to Sobi
s focus on Synagis will enable infants in the US to continue benefiting from this important treatment.”. ... The addition of Synagis will become an important strategic catalyst for Sobi’s future development and will form a powerful platform for
Ablynx spurns Novo Nordisk and cuts €3.9bn deal with Sanofi
AZ sells a prophylactic RSV antibody - Synagis (palivizumab) - which brought in $677m in sales in 2016 despite being reserved for use in high-risk infants.
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
Featured jobs
- Director of Scientific Services, Medical Communications, Six fig...
-
Six figure salary
-
Consultant
-
competitive salary
-
Vice President
-
Competitive Salary Offered
- Account Manager– Medical Communications
-
(Negotiable - depending on experience)
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Senior Medical Writer, MedComms Agency
-
Salary TBC
- Account Director or Senior Account Director
-
Salary TBC
-
Principal Medical Writer
-
£48 - 58, 000 according to skills and experience benefits
Subscribe to our email news alerts
- Moving annual total (MAT)
- FDA starts priority review of BMS Opdivo/Yervoy in first-line NSCLC
- NantKwest rockets on promising pancreatic cancer data
- Novo Nordisk gets MACE prevention claim for Ozempic in US
- Clovis leapfrogs PARP rivals, filing Rubraca for prostate cancer
- Latecomer Lilly preps its IL-23 drug for Crohn’s disease
- My Journey into Medical Communications #LucidLife
- Novartis gets EU approval for multiple sclerosis therapy Mayzent
- J&J wins another label expansion for Darzalex in Europe
- EU grants conditional approval to Roche's lymphoma drug Polivy
- Immuno-oncology, personalised medicine continues to drive pharma sector
- OPEN Health expands offering with the launch of a new Learning & Development specialist team
PMHub
Market Access Transformation
Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...
Latest intelligence
- OPEN Health expands offering with the launch of a new Learning & Development specialist team
- Enhanced expertise to deliver impactful internal training programmes for healthcare clients...
- The changing nature of approvals – what does the future hold?
- The 2019 CMR International Pharmaceutical R&D Factbook...
- Spotlight interview: 15 minutes on healthcare communications in gene therapy
- Gavin Jones, Director of Rare Disease, OPEN Health takes 15 minutes to answer some key questions on healthcare communications in gene therapy...
Quick links
Infographics
